NCT06170710View on ClinicalTrials.gov

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2027

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Anti-PD-1 monoclonal antibody

"Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:~Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W"

OTHER

Postoperative CCRT

Postoperative chemoradiotherapy

Trial Locations (1)

100021

RECRUITING

National Cancer Cencer/Cancer hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER